Prostate cancer gene therapy clinical trials

Molecular Therapy

Volumn 15, Issue 6, 2007, Pages 1042-1052

  Freytag, Svend O ^a   Stricker, Hans ^a   Movsas, Benjamin ^a   Kim, Jae Ho ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CG 7870; CV 706; CYTOSINE DEAMINASE; DOCETAXEL; FLUCYTOSINE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LIPOSOME; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; ONCOLYTIC ADENOVIRUS; ORNITHINE CARBAMOYLTRANSFERASE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GENE EXPRESSION; HEMATOLOGIC DISEASE; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INJECTION PAIN; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INTENSITY MODULATED RADIATION THERAPY; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALAISE; METASTASIS; NEUTROPENIA; NONHUMAN; NONVIRAL GENE THERAPY; ONCOLYTIC VIROTHERAPY; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RADIOSENSITIZATION; RECTUM HEMORRHAGE; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SKIN MANIFESTATION; SUICIDE GENE THERAPY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VIRAL GENE THERAPY;

CLINICAL TRIALS; GENE THERAPY; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 34249279186     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300162     Document Type: Review

References (97)

1. American Cancer Society (2007). Cancer Facts and Figures 2007. American Cancer Society.
2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission.
3. Herman, JR, Adler, HL, Aguilar-Cordova, E, Rojas-Martinez, A, Woo, S, Timme, TL et al. (1999). In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial. Hum Gene Ther 10: 1239-1249.
4. Miles, BJ, Shalev, M, Aguilar-Cordova, E, Timme, TL, Lee, HM, Yang, G et al. (2001). Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 12: 1955-1967.
5. Teh, BS, Aguilar-Cordova, E, Kernen, K, Chou, CC, Shalev, M, Vlachaki, MT et al. (2001). Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer - a preliminary report. Int J Radiat Oncol Biol Phys 51: 605-613.
6. DeWeese, TL, van der Poel, H, Li, S, Mikhak, B, Drew, R, Goemann, M et al. (2001). A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61: 7464-7472.
7. Freytag, SO, Khil, M, Stricker, H, Peabody, J, Menon, M, DePeralta-Venturina, M et al. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62: 4968-4976.
8. Freytag, SO, Stricker, H, Pegg, J, Paielli, D, Pradhan, DG, Peabody, J et al. (2003). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy in combination with conventional dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63: 7497-7506.
9. Teh, BS, Ayala, G, Aguilar, L, Mai, WY, Timme, TL, Vlachaki, MT et al. (2004). Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 58: 1520-1529.
10. Freytag, S, Stricker, H, Peabody, J, Pegg, J, Paielli, D, Movsas, B et al. (2007). Five-year follow-up of clinical trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 15: 636-642.
11. Freytag, S, Movsas, B, Aref, I, Stricker, H, Peabody, J, Pegg, J et al. (2007). Phase I trial of replication-competent adenovirus-mediated suicide gene therapy in combination with IMRT for the treatment of newly-diagnosed prostate cancer. Mol Ther published online 20 March 2007 (doi: 10.1038/mt.sj.6300120).
12. Kim, JH, Kim, SH, Brown, SL and Freytag, SO (1994). Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res 54: 6053-6056.
13. Khil, MS, Kim, JH, Mullen, CA, Kim, SH and Freytag, SO (1995). Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res 2: 53-57.
14. Freytag, SO, Rogulski, KR, Paielli, DL, Gilbert, JD and Kim, JH (1998). A novel three-pronged approach to selectively kill cancer cells: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 9: 1323-1333.
15. Rogulski, KR, Wing, MS, Paielli, DL, Gilbert, JD, Kim, JH and Freytag, SO (2000). Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 11: 67-76.
16. Rogulski, KR, Freytag, SO, Zhang, K, Gilbert, JD, Paielli, DL, Kim, JH et al. (2000). In vivo anti-tumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 60: 1193-1196.
17. Freytag, SO, Paielli, D, Wing, M, Rogulski, K, Brown, S, Kolozsvary, A et al. (2002). Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 54: 873-885.
18. Culver, KW, Ram, Z, Wallbridge, S, Ishii, H, Oldfield, EH and Blaese, RM (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256 1550-1552.
19. Takamiya, Y, Short, MP, Ezzeddine, ZD, Moolten, FL, Breakefield, XO and Martuza, RL (1992). Gene therapy of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res 33 493-503.
20. Huber, BE, Austin, EA, Richards, CA, Davis, ST and Good, SS (1994). Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91: 8302-8306.
21. Rodriguez, R, Schuur, ER, Lim, HY, Henderson, GA, Simons, JW and Henderson, DR (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57: 2559-2563.
22. Pollack, A, Zagars, GK and Kavadi, VS (1994). Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74: 670-678.
23. Zagars, GK and Pollack, A (1997). Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44: 213-221.
24. Sartor, CI, Strawderman, MH, Lin, XH, Kish, KE, McLaughlin, PW and Sandler, HM (1997). Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 38: 941-947.
25. Sandler, HM, Dunn, RL, McLaughlin, PW, Hayman, JA, Sullivan, MA and Taylor, JM (2000). Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 48: 629-633.
26. D'Amico, AV, Cote, K, Loffredo, M, Renshaw, AA and Schultz, D (2002). Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20: 4567-4573.
27. D'Amico, AV, Moul, JW, Carroll, PR, Sun, L, Lubeck, D and Chen, MH (2003). Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376-1383.
28. D'Amico, AV, Chen, MH, Roehl, KA and Catalona, WJ (2004). Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125-135.
29. Lee, AK, Levy, LB, Cheung, R and Kuban, D (2005). Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63: 456-462.
30. Patel, DA, Presti, JC Jr., McNeal, JE, Gill, H, Brooks, JD and King, CR (2005). Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 23: 6157-6162.
31. Freedland, SJ, Humphreys, EB, Mangold, LA, Eisenberger, M, Dorey, FJ and Walsh, PC et al. (2005). Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294: 433-439.
32. D'Amico, AV, Kantoff, P, Loffredo, M, Renshaw, AA, Loffredo, B and Chen, MH (2006). Predictors of mortality after prostate-specific antigen failure. Int J Radiat Oncol Biol Phys 65: 656-660.
33. Valicenti, RK, DeSilvio, M, Hanks, GE, Porter, A, Brereton, H, Rosenthal, SA et al. (2006). Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer specific survival: An analysis of radiation therapy oncology group protocol 92-02. Int J Radiat Oncol Biol Phys 66: 1064-1071.
34. Caruso, M, Panis, Y, Gagandeep, S, Houssin, D, Salzmann, JL and Klatzmann, D (1993). Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 90: 7024-7028.
35. Mullen, CA, Coale, MM, Lowe, R and Blaese, RM (1994). Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor. Cancer Res 54: 1503-1506.
36. Barba, D, Hardin, J, Sadelain, M and Gage, FH (1994). Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 91: 4348-4352.
37. Vile, RG, Nelson, JA, Casleden, S, Chong, H and Hart, IR (1994). Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54: 6228-6234.
38. Consalvo, M, Mullen, CA, Modesti, A, Musiani, P, Allione, A, Cavallo, F et al. (1995). 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 154: 5302-5312.
39. Vile, RG, Castleden, S, Marshall, J, Camplejohn, R, Upton, C and Chong, H (1997). Generation of an anti-tumor immune response in a non-immunogenic tumor: HSVtk-killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression. Int J Cancer 71: 267-274.
40. Melcher, A, Todryk, S, Hardwick, N, Ford, M, Jacobson, M and Vile, RG (1998). Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 4 581-587.
41. Hanna, NN, Mauceri, HJ, Wayne, JD, Hallahan, DE, Kufe, DW and Weichselbaum, RR (1997). Virally directed cytosine deaminase/ 5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res 57: 4205-4209.
42. Kievit, E, Bershad, E, Ng, E, Sethna, P, Dev, I, Lawrence, TS et al. (1999). Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 59: 1417-1421.
43. Hamstra, DA, Rice, DJ, Fahmy, S, Ross, BD and Rehemtulla, A (1999). Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther 10: 1993-2003.
44. Stackhouse, MA, Pederson, LC, Grizzle, WE, Curiel, DT, Gebert, J, Haack, K et al. (2000). Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther 7: 1019-1026.
45. Kievit, E, Nyati, MK, Ng, E, Stegman, LD, Parsels, J, Ross, BD et al. (2000). Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res 60: 6649-6655.
46. Vlachaki, MT, Chhikara, M, Aguilar, L, Zhu, X, Chiu, KJ, Woo, S et al. (2001). Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys 51: 1008-1017.
47. Black, ME, Kokoris, MS and Sabo, P (2001). Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 61: 3022-3026.
48. Tollefson, AE, Scaria, A, Hermiston, TW, Ryerse, JS, Wold, LJ and Wold, WS (1996). The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 70: 2296-2306.
49. Tollefson, AE, Ryerse, JS, Scaria, A, Hermiston, TW and Wold, WS (1996). The E3-11.6 kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants. Virology 220: 152-162.
50. Doronin, K, Toth, K, Kuppuswamy, M, Ward, P, Tollefson, AE and Wold, WS (2000). Tumor-specific, replication-competent adenovirus vectors over-expressing the adenovirus death protein. J Virol 74: 6147-6155.
51. Doronin, K, Kuppuswamy, M, Toth, K, Tollefson, AE, Krajcsi, P, Krougliak, V et al. (2001). Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 75: 3314-3324.
52. Toth, K, Tarakanova, V, Doronin, K, Ward, P, Kuppuswamy, M, Locke, JE et al. (2003). Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther 10: 193-200.
53. Barton, KN, Paielli, D, Zhang, Y, Koul, S, Brown, SL, Lu, M et al. (2006). Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther 13: 347-356.
54. Pollack, A, Zagars, GK, Smith, LG, Lee, JJ, von Eschenbach, AC, Antolak, JA et al. (2000). Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18: 3904-3911.
55. Pollack, A, Zagars, GK, Starkschall, G, Antolak, JA, Lee, JJ, Huang, E et al. (2002). Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53: 1097-1105.
56. Zelefsky, MJ, Fuks, Z, Hunt, M, Lee, HJ, Lombardi, D, Ling, CC et al. (2001). High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166: 876-881.
57. Crook, JM, Perry, GA, Robertson, S and Esche, BA (1995). Routine prostate biopsies following radiotherapy for prostate cancer: Results for 226 patients. Urology 45: 624-632.
58. Crook, JM, Bahadur, YA, Robertson, SJ, Perry, GA and Esche, BA (1997). Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer 79: 81-89.
59. Crook, JM, Bahadur, YA, Bociek, RG, Perry, GA, Robertson, SJ and Esche, BA (1997). Radiotherapy for localized prostate carcinoma: The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer 79: 328-336.
60. Crook, J, Malone, S, Perry, G, Bahadur, Y, Robertson, S and Abdolell, M (2000). Postradiotherapy prostate biopsies: What do they really mean? results for 498 patients. Int J Radiat Oncol Biol Phys 48: 355-367.
61. Scardino, PT and Wheeler, TM (1988). Local control of prostate cancer with radiotherapy. Frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr 7: 95-103.
62. Kuban, DA, el-Mahdi, AM and Schellhammer, P (1992). The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys 24: 409-414.
63. Prestidge, BR, Kaplan, I, Cox, RS and Bagshaw, MA (1992). The clinical significance of a positive post-irradiation prostatic biopsy without metastases. Int J Radiat Oncol Biol Phys 24: 403-408.
64. Hemmi, S, Geertsen, R, Mezzacasa, A, Peter, I and Drummer, R (1998). The presence of human coxsackie and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Gene Ther 9: 2363-2373.
65. Richardson, C, Brennan, P, Powell, M, Prince, S, Chen, YH, Spiller, OB et al. (2005). Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackie-adenovirus receptor and alphavbeta 5 integrin expression. J Gen Virol 86: 1669-1679.
66. Li, Y, Pong, RC, Bergelson, JM, Hall, MC, Sagalowsky, AI, Tseng, CP et al. (1999). Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res 59: 325-330.
67. Okegawa, T, Li, Y, Pong, RC, Bergelson, JM, Zhou, J and Hsieh, JT (2000). The dual impact of coxsackie and adenovirus receptor expression in human prostate cancer gene therapy. Cancer Res 60: 5031-5036.
68. Rauen, KA, Sudilovsky, D, Le, JL, Chew, KL, Hann, B, Weinberg, V et al. (2002). Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy. Cancer Res 62: 3812-3818.
69. Fleshner, NE, O'Sullivan, M and Fair, WR (1997). Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 158: 505-509.
70. Epstein, JI, Walsh, PC, Sauvageot, J and Carter, HB (1997). Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 158: 1886-1890.
71. Norberg, M, Egevad, L, Holmberg, L, Sparen, P, Norlen, BJ and Busch, C (1997). The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50: 562-566.
72. Svetec, D, McCabe, K, Peretsman, S, Klein, E, Levin, H, Optenberg, S et al. (1998). Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. J Urol 159: 1606-1608.
73. Eskew, LA, Bare, RL and McCullough, DL (1997). Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157: 199-203.
74. Belldegrun, A, Tso, CL, Zisman, A, Naitoh, J, Said, J, Pantuck, AJ et al. (2001). Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology. Hum Gene Ther 12: 883-892.
75. Kubo, H, Gardner, TA, Wada, Y, Koeneman, KS and Gotoh, A (2003). Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 14 227-241.
76. Koeneman, KS, Kao, C, Ko, SC, Yang, L, Wada, Y, Kallmes, DF et al. (2000). Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 18: 102-110.
77. Small, EJ, Carducci, MA, Burke, JM, Rodriguez, R, Fong, L, van Ummersen, L et al. (2006). A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14: 107-117.
78. Raper, SE, Chirmule, N, Lee, FS, Wivel, NA, Bagg, A, Gao, GP et al. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-158.
79. Imperiale, MJ, Kao, HT, Feldman, LT, Nevins, JR and Strickland, S (1984). Common control of the heat shock gene and early adenovirus genes: Evidence of a cellular E1a-like activity. Mol Cell Biol 4: 867-874.
80. Spergel, JM and Chen-Kiang, S (1991). Interleukin 6 enhances a cellular activity that functionally substitutes for E1a protein in transactivation. Proc Natl Acad Sci USA 88: 6472-6476.
81. Spergel, JM, Hsu, W, Akira, S, Thimmappaya, B, Kishimoto, T and Chen-Kiang, S (1992). NF-IL6, a member of the C/EBP family, regulates E1A-reponsive promoters in absence of E1A. J Virol 66: 1021-1030.
82. Nelson, JE and Kay, MA (1997). Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication. J Virol 71: 8902-8907.
83. Simons, JW, Mikhak, B, Chang, JF, DeMarzo, A, Carducci, MA, Lim, M et al. (1999). Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59: 5160-5168.
84. Dranoff, G, Jaffee, E, Lazenby, A, Golumbek, P, Levitsky, H, Brose, K et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543.
85. Simons, J, Nelson, W, Nemuniatis, J, Centeno, A, Dula, E, Urba, W et al. (2002). Phase II trials of a GMCSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 22: 172.
86. Small, E, Higano, C, Smith, D, Corman, J, Centero, A, Streidle, C et al. (2004). A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol 22: 4565.
87. Sanda, MG, Ayyagari, SR, Jaffee, EM, Epstein, JI, Clift, SL, Cohen, LK et al. (1994). Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151: 622-628.
88. Sanda, MG, Smith, DC, Charles, LG, Hwang, C, Pienta, KJ, Schlom, J et al. (1999). Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53: 260-266.
89. Eder, JP, Kantoff, PW, Roper, K, Xu, GX, Bubley, GJ, Boyden, J et al. (2000). A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6: 1632-1638.
90. Gulley, J, Chen, AP, Dahut, W, Arlen, PM, Bastian, A, Steinberg, SM et al. (2002). Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic, androgen-independent prostate cancer. Prostate 53: 109-117.
91. Kaufman, HL, Wang, W, Manola, J, DiPaola, RS, Ko, YJ, Sweeney, C et al. (2004). Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 22: 2122-2132.
92. DiPaola, R, Plante, M, Kaufman, H, Petrylak, D, Israeli, R, Lattime, E et al. (2006). A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Translational Med 4: 1-5.
93. Liu, TC and Kirn, D (2007). Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions. Cancer Res. 67: 429-432.
94. Satoh, T, Teh, BS, Timme, TL, Mai, WY, Gdor, Y, Kusaka, N et al. (2004). Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 59: 562-571.
95. Fujita, T, Teh, BS, Timme, TL, Mai, WY, Satoh, T, Kusaka, N et al. (2006). Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 65: 84-90.
96. Barton, KN, Tyson, D, Stricker, H, Lew, YS, Heisey, G, Koul, S et al. (2003). GENIS: Gene expression of sodium iodide symporter for non-invasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol Ther 8: 508-518.
97. Small, EJ, Schellhammer, PF, Higano, CS, Redfern, CH, Nemunaitis, JJ, Valone, FH et al. (2006). Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24: 3089-3094.